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EDITORIAL REVIEW
Prostaglandins: Effects on blood pressure, renal blood flow,
sodium and water excretion
The prostaglandins are naturally occurring unsatu-
rated fatty acids which have been implicated in a
variety of physiologic and pathophysiologic proc-
esses involving organ function, One of the most strik-
ing actions of prostaglandins of the E and A series is
their capacity to dilate peripheral blood vessels and
thereby to lower arterial pressure. This vasodilating
effect of prostaglandins may be mediated by altera-
tions in circulating blood levels of the hormone(s) or
by changes in concentration of prostaglandins in
blood vessel walls. Prostaglandins also have been
implicated in the regulation of the renin-angiotensin-
aldosterone system. In addition, a direct effect of
prostaglandins in modulating both renal blood flow
and renal tubular sodium reabsorption has been sug-
gested. An effect of prostaglandins to inhibit the ac-
tion of vasopressin to increase water permeability in
the mammalian collecting duct also has been pro-
posed. In the present editorial we will briefly survey
the evidence for and against the proposed actions of
prostaglandins in regulating blood pressure, renal
blood flow and renal sodium and water excretion.
Prostaglandins and control of blood pressure
Prostaglandins as circulating vasodilators. A great
deal of evidence has accumulated to indicate that the
kidney is capable not only of promoting an increase
in blood pressure, but also of preventing sustained
elevations in blood pressure [1]. There seems little
doubt that part of the antihypertensive function of
the kidney is attributable to its ability to regulate
extracellular fluid (ECF) volume [2]. However, sev-
eral lines of investigation also indicate that the kidney
elaborates a humoral agent, possibly a prostaglandin,
which helps to lower the blood pressure [2,3].
The most troublesome source of controversy about
renal prostaglandins and their role in blood pressure
control relates to the types of prostaglandins synthe-
sized by the kidney. While there is general agreement
that PGF2a, a nonvasodepressor prostaglandin, is
Received for publication January 15, 1976;
and in revised form March IS, 1976.
© 1976, by the International Society of Nephrology.
205
synthesized in relatively small quantities by the kid-
ney and that PGE2 is the most abundantly synthe-
sized renal prostaglandin [4], there is no consensus
regarding the synthesis of PGA compounds by the
kidney. The question about the existence of PGA in
the kidney and in renal venous blood is of critical
importance, since PGA largely escapes inactivation
during passage through the pulmonary circulation
[5,6]. This property of PGA would make it capable of
achieving significant concentrations in systemic arte-
rial blood, and therefore of acting as a circulating
vasoactive agent.
There is, however, considerable controversy as to
whether PGA is a hormone which circulates in the
blood stream in vivo and, if so, whether the present
methodology is both specific and sensitive enough to
measure the circulating concentrations. Lee and At-
tallah [3] have published evidence for high concentra-
tions of PGA2 in the renal medulla and in renal
venous blood using a radioimmunoassay technique.
This radioimmunoassay data also was supported by
gas chromatographic and thin layer chromatographic
techniques [3]. The studies of Lee and Attallah [3,7]
also indicate that significant concentrations of PGA
exist in systemic arterial blood and these workers
have suggested that the kidney is the primary source
of the PGA in systemic blood. Since pharmacologic
studies have indicated that infused PGA is natriuretic
and also causes peripheral and renal vasodilatation,
prostaglandins of the PGA series are excellent can-
didates to be endogenous antihypertensive hormones
[7-10]. In an effort to determine whether a deficiency
in PGA might contribute to hypertensive states in
man, Lee and Attallah [3] have measured PGA blood
concentrations in patients with essential hyperten-
sion. Their results suggest that patients with essential
hypertension have decreased circulating concentra-
tions of PGA.
Some conflict, however, has developed about these
above findings. On the one hand, the studies of Zus-
man et al [11] support the findings of Lee and Attal-
Iah [3] in that patients with essential hypertension
were shown to have decreased systemic blood con-
centrations of PGA in comparison to normotensive
subjects. However, other investigators have been
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unable to measure PGA in renal tissue, renal venous
blood or systemic blood in man [12-15]. One pro-
posed explanation is that the PGA measured in ex-
tracts of human and rabbit renal tissue may have
originated from the conversion of renal PGE to PGA
during the in vitro extraction procedure [14]. These
latter observations, therefore, do not support the
existence of PGA as naturally occurring compounds
[12-15]. It is thus impossible, on the basis of pub-
lished results, to determine whether PGA deficiency
exists in vivo and is important in the pathogenesis of
hypertension. There does, however, seem to be some
agreement that mass spectroscopy is the most sensi-
tive and specific means presently available to measure
PGA and it is using this method that some in-
vestigators have failed to detect in vivo concentra-
tions of PGA [12].
A word about the potential importance of PGE is
appropriate. In contrast to PGA, there is no doubt
about the in vivo existence of prostaglandins of the E
series [16]. Nevertheless, a potential role of these
hormones in control of arterial blood pressure has
been questioned because they are avidly extracted by
the lungs prior to reaching the arterial circulation
[5,6]. However, recent results of metabolic clearance
studies in man indicate that as much as one-third of
PGEI may escape lung metabolism [17]. This might
explain why some investigators have been able to
measure significant concentrations of prostaglandins
of the E series in arterial blood of experimental ani-
mals. Moreover, it has been suggested that the extrac-
tion of prostaglandins by the lung may be altered
during certain pathologic circumstances such as he-
morrhage [18]. These results, therefore, indicate that,
although avidly extracted by the lung, the pros-
taglandins of the F series could be potentially impor-
tant as systemic humoral agents involved in blood
pressure control.
Other experimental evidence has been developed
by Muirhead [1,19] which implicates renomedullary
humoral factors in blood pressure control. Auto- or
isotransplants of renomedullary tissue placed sub-
cutaneously or intraperitoneally in dogs, rats and
rabbits with experimental hypertension have been
found to lower blood pressure to control levels and to
maintain a normotensive state until the transplant is
removed [1,19]. Thereafter, the blood pressure rap-
idly rises to pretransplant hypertensive levels. This
antihypertensive action of renomedullary tissue ap-
pears to be equally effective in a wide variety of
hypertensive models, including one- and two-kidney
renovascular hypertension; hypertension induced by
mineralocorticoids or salt-loading, angiotensin-in-
duced hypertension; and renoprival hypertension
[1,19]. As Muirhead has recently indicated [19], the
mechanism by which the renomedullary transplants
exert their antihypertensive effect is still uncertain.
The available evidence strongly suggests that the ac-
tive substance(s) is produced by medullary interstitial
cells and is synthesized, and/or stored, in the lipid
granules in these cells.
The major question that arises from these studies
relates to the composition of the lipid soluble sub-
stance(s) produced by the interstitial cells. It seems
clear that at least part of the lipid soluble extracts
from these cells is composed of prostaglandins [1,201;
however, other substances may account for the
depressor action of renomedullary cells. For ex-
ample, Muirhead [19] has extracted from the renome-
dullary interstitial cells a vasodepressor lipid which
he has termed "antihypertensive neutral renome-
dullary lipid" (ANRL). This substance has not been
identified but it does not appear to be a pros-
taglandin.
Prostaglandins as local vasodilators. It also has
been proposed that prostaglandins might act locally
in arterial walls to influence vascular tone [21]. This
hypothesis is attractive, since it obviates the need for
prostaglandins to act as circulating humoral agents.
Several studies have indicated that locally synthesized
prostaglandins might not only affect vascular tone
directly, but also may modulate the response of vas-
cular smooth muscle to other vasoactive agents [21].
Prostaglandins in vessel walls may interfere with the
local release of the norepinephrine [22] and pros-
taglandins of the E series have been shown to blunt
the response of vascular smooth muscle to angioten-
sin [23] and norepinephrine [24]. These latter vaso-
constrictors also are capable of stimulating PGE pro-
duction [21]. This raises the possibility that the
ultimate effect of angiotensin or norepinephrine on
vascular resistance is the result of a balance between
the degree of smooth muscle contraction induced and
the amount of prostaglandin production stimulated
in the vessel wall. A corrollary to this hypothesis is
that the responsiveness of a vascular bed to the vaso-
constrictor actions of norepinephrine and angioten-
sion II should be enhanced when prostaglandin pro-
duction is inhibited. This reciprocity of effects
between prostaglandins and vasoconstrictor agents
has been demonstrated in rabbit coeliac artery strips
[25], renal blood vessels [25] and the vasculature of
the rabbit ear [26].
Obviously, if prostaglandins in vascular beds exert
a significant effect on vascular tone and on respon-
siveness of the vessels to vasoactive stimuli, they
could be important in the pathogenesis of hyperten-
sion. Although such a role for the vascular pros-
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taglandins is conjectural, there are indications that
prostaglandin deficiency may cause a rise in per-
ipheral resistance and blood pressure in experimental
animals. Indomethacin and meclofenamate, both in-
hibitors of prostaglandin synthesis, have been shown
to cause a rise in peripheral resistance in the anesthe-
tized dog [27], rabbit [281 and man [29]. Unfortu-
nately, an effect of these drugs on blood pressure
independent of prostaglandin synthesis cannot be ex-
cluded. Nevertheless, additional indications that pros-
taglandin deficiency might contribute to experimen-
tal hypertension have been provided by the study of
Rosenthal, Simone and Silbergleit [30]. These work-
ers demonstrated that prostaglandin depletion in-
duced by a diet deficient in arachidonic acid, the
precursor of prostaglandin biosynthesis, increased
the rate at which hypertension developed in rats re-
ceiving a high salt intake. Moreover, Cohen, Szto-
kalo and Hirsch [31] have shown that administration
of arachidonic acid to spontaneously hypertensive
(SH) rats reduced their blood pressure; and Pugsley,
Beilin and Peto [32] demonstrated that PGE syn-
thesis in the renal medulla of rats with Goldblatt
hypertension is decreased. These findings which sug-
gest that prostaglaridin deficiency may contribute to
some forms of hypertension in the rat, however, are
difficult to reconcile with the findings of Malik and
McGiff [33]. These workers have demonstrated that
in the rat infused PGE actually increases blood pres-
sure. This observation would suggest that PGE defi-
ciency should be hypotensive rather than hyperten-
sive in the rat. The physiologic vs. pharmacologic
implications of this study, however, remain to be
determined.
An intriguing case report of Zusman et al does
suggest an antihypertensive role for endogenous pros-
taglandins in man [34]. In a patient with long-stand-
ing hypertension, the development of a renal cell
carcinoma was associated with lowering of blood
pressure and high plasma PGA concentrations. On
removal of the tumor, plasma PGA concentrations
fell to normal. Coincident with this decrease in the
circulating PGA concentration, the blood pressure
rose to its previous hypertensive levels. This observa-
tion clearly does not establish a physiologic role for
PGA in blood pressure control, but it does suggest
such a role in this pathologic setting.
In view of the difficulties encountered in estab-
lishing an antihypertensive role for circulating or tis-
sue prostaglandins, efforts have been made to deter-
mine whether prostaglandins might exert indirect
effects that would alter blood pressure. Two major
possibilities have received the most consideration: 1)
that the renal prostaglandins alter the renin-angioten-
sin-aldosterone system, and 2) that the renal pros-
taglandins influence the role of the kidney in regu-
lating ECF volume.
Pros taglandins and renin-angiotensin-aldosterone
system. In anesthetized dogs, the infusion of PGE1
into the renal artery has been reported to result in
either no change [35] or an increase in rena' venous
renin concentration [36]. The intrarenal infusion of
arachidonic acid, a precursor for prostaglandin syn-
thesis, has been shown to enhance renal renin pro-
duction in anesthetized rabbits [37]. In man, non-
vasodepressor doses of PGA, administered i.v., were
not found to alter plasma renin activity [38]. The
in vitro renin reaction, however, has been shown to
be inhibited by PGA [39]. Preliminary studies also
have demonstrated that indomethacin inhibits renal
renin release in rabbit [40] and man [29]. These latter
results suggest that endogenous prostaglandins in-
deed may act to stimulate renin release. Alternatively,
some action of indomethacin other than the inhibi-
tion of prostaglandin synthetase may account for the
suppression of renin. Thus, from these above find-
ings, an effect of endogenous prostaglandins to stim-
ulate renin release is possible, but cannot be consid-
ered to be established.
A few studies examining the effects of pros-
taglandins on aldosterone secretion or synthesis also
have been performed. In man, nonvasodepressor
doses of PGA, administered i.v., were found to in-
crease plasma aldosterone concentrations in the ab-
sence of a rise in plasma renin activity [38]. More
recently, however, these same workers have indicated
that the effect of PGA to stimulate aldosterone secre-
tion in man generally correlates closely with a simul-
taneous renin stimulating effect [41]. Indomethacin
also has been found to suppress aldosterone excretion
in man [41]. In a recent study in man, a significant
direct correlation between urinary aldosterone and
plasma PGA concentrations could be found [42].
Prostaglandins have also been demonstrated to en-
hance the in vitro biosynthesis of aldosterone [43].
However, as previously discussed, the in vivo exis-
tence of PGA is controversial and indomethacin may
exert effects independent of prostaglandin inhibition.
Taken together, therefore, the evidence to date is
insufficient to establish conclusively that the pros-
taglandins participate in the physiologic control of
renin or aldosterone secretion. Furthermore, if en-
dogenous prostaglandins do stimulate renin and al-
dosterone, the resultant increased vasoconstriction
and sodium retention would tend to increase blood
pressure, an effect opposite of any direct vasodilating
effect of circulating or local prostaglandins.
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Prostaglandins and renal sodium excretion
Another means whereby prostaglandins may alter
blood pressure is by a direct effect on renal sodium
excretion and, thus, ECF volume. For example, if the
prostaglandins are natriuretic, then a deficiency of
prostaglandins would result in enhanced renal so-
dium conservation and should aggravate hyperten-
sion. When infused either i.v. or into the renal artery,
prostaglandins of the E and A series do result in a
concomitant increase in renal blood flow and an in-
crease in renal sodium excretion in anesthetized dogs
[35,44—48] and conscious man [9,10,38,49]. On the
basis of clearance studies which demonstrate an in-
crease in free water clearance associated with the
natriuresis of prostaglandin infusion, it appears that
intrarenal prostaglandin infusions decrease sodium
reabsorption in the proximal tubule [44,46,47]. in
addition, the results of micropuncture studies also
suggest more distal nephron sites of actions of pros-
taglandins [47]. It is important to note, however,
that all of these studies utilized pharmacologic doses
of prostaglandin [9,10,35,38,44—49] and the in-
trarenal infusion of these substances may not mimic
their usual medullary location. Furthermore, the na-
triuresis of prostaglandin infusion appears to be sim-
ilar to that obtained with the intrarenal infusion of
other renal vasodilators [44], thus suggesting a non-
specific hemodynamic effect.
The most convincing evidence to date that endog-
enous prostaglandins may be natriuretic has been the
demonstration of Tannenbaum et al [50] that the
intrarenal infusion of arachidonic acid to anesthe-
tized dogs results in ipsilateral increases in sodium
excretion and prostaglandin-like substances in renal
venous efiuent [50]. Furthermore, enhanced renal
sodium excretion could be demonstrated with doses
of arachidonate (<3 tg/kg/min) which did not alter
glomerular filtration rate or renal blood flow and this
natriuresis could be abolished by the administration
of an inhibitor of prostaglandin synthesis [50]. At
variance with these findings, however, are the recent
preliminary reports of Kirschenbaum et al [51] dem-
onstrating that arachidonic acid does not increase
renal sodium excretion in the prostaglandin-depleted
kidney. These workers also recently have demon-
strated [52] that while both prostaglandin inhibition
and intrarenal angiotensin have similar renal he-
modynamic effects in anesthetized dogs, angiotensin
decreases and prostaglandin inhibition increases
renal sodium excretion in response to volume expan-
sion. Moreover, inhibition of prostaglandin synthesis
with meclofenamate or the new competitive inhibitor,
RO 20-572, caused a natriuresis in the conscious dog
[53]. Thus, in contrast to previous proposals, these
latter results suggest that endogenous prostaglandins
may decrease sodium excretion, an effect that should
raise rather than lower blood pressure.
An explanation for the differences observed in
these above studies may be the fact that pros-
taglandins may affect renal sodium excretion by
more than one mechanism, i.e., by a direct effect on
sodium transport and by effects on renal hemody-
namics. In vitro studies suggest that PGE1 has a direct
effect to enhance transmembrane sodium transport
[54—56]. When PGEI is applied to the serosal surface
of the toad bladder, significant increases in short
circuit current and active sodium transport result
[54]. Similar findings have been demonstrated utiliz-
ing frog skin [55,57]. It is therefore possible that
prostaglandins could decrease renal sodium excretion
by enhancing tubular sodium reabsorption. This anti-
natriuretic effect, however, could be obscured by the
effect of prostaglandins to cause renal vasodilatation
and thus to decrease tubular sodium reabsorption.
Compatible with this interpretation is the finding that
inhibition of prostaglandin synthesis may increase
renal vascular resistance and decrease blood flow in
the anesthetized dog [57—60] but not conscious dog or
baboon [53,61,62]. At the same time no change or a
decrease in urinary sodium excretion has been ob-
served in the anesthetized dog during indomethacin
administration [63] while, as already mentioned,
meclofenamate and RO 20-572 have been found to
increase urinary sodium excretion in the conscious
dog [53]. Gill et al [64] also recently have demon-
strated an increase in sodium excretion during in-
trarenal indomethacin infusion in the anesthetized,
hypophysectomized dog and have suggested that
ECF expansion may suppress distal tubular sodium
reabsorption in part by suppressing renal prostaglan-
din content.
In the context of these preliminary observations
[53,64], prostaglandin inhibition with indomethacin
might be expected to increase sodium excretion in
conscious man. However, indomethacin recently has
been found to be an effective drug in treating the
renal sodium and potassium wasting in patients with
Bartter's syndrome [65,66] and to attenuate a furose-
mide-induced natriuresis in hypertensive subjects
[29]. Thus, while these above observations are inter-
esting, further studies are needed before definitive
conclusions can be drawn.
The effects of sodium loading or sodium depletion
on plasma prostaglandins and renal tissue pros-
taglandin concentrations also have been examined
and results are conflicting. Zusman et al [67] and
Payakkapan et al [42] reported that plasma PGA
concentrations are suppressed with high and stimu-
lated with low sodium diets in man. The former
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group, however, has been unable to confirm their
findings (Muirow P: personal communication). In
animal studies, high sodium intake has been reported
to decrease renal PGE content, and to diminish pa-
pillary PGA content [68,69]. Again, however, the
existence of de novo PGA in renal tissue has been
questioned [151 and methodology problems in extrac-
tion of renal tissue prostaglandins have not been
resolved [61].
In summary, the question as to whether endogen-
ous plasma or renal concentrations of prostaglandins
affect renal sodium excretion remains unresolved,
Hence, any effect of prostaglandins in regulating
blood pressure through inducing changes in ECF
volume remains speculative.
Prostaglandins and renal blood flow
Several lines of evidence suggest that prostaglandins
may be important in the regulation of renal blood
flow. Numerous investigations in anesthetized dogs
and hypertensive man have demonstrated that the
intrarenal administration of prostaglandins of the
E or A series results in increases in renal blood flow
[9,10,35,44—46,70,71]. However, pharmacologic doses
of prostaglandins have been used in most of these
studies and therefore the results may not imply a
relationship of prostaglandins to a physiologic con-
trol system.
Tannenbaum et al [50] enhanced endogenous renal
prostaglandin synthesis in the anesthetized dog by the
intrarenal administration of >3 tg/kg/min of the
prostaglandin precursor, sodium arachidonate. In
these studies the administration of sodium arachido-
nate resulted in concomitant increases in renal blood
flow and renal venous prostaglandin-like substances
[50]. However, sodium arachidonate is unstable in
solution and could be auto-oxidized to a vasoactive
prostaglandin-like substance or converted to vasoac-
tive hydroxy acids during the renal arterial infusion
[72,73]. The demonstration that an inhibitor of pros-
taglandin synthesis abolished the arachidonate-in-
duced increases in renal blood flow therefore strength-
ened their contention that endogenous prostaglandins
may increase renal blood flow in the mammalian
kidney [501. Since some prostaglandin synthetase may
reside in renal cortex as well as the medulla [74], an
infusion of arachidonic acid may increase both cor-
tical and medullary blood flow. However, because of
the greater activity in the cortex of the prostaglandin
degradative enzymes, the major physiologic effect of
prostaglandin is probably exerted in the medulla.
The administration of prostaglandin inhibitors,
such as indomethacin or meclofenamate, also has
been found to decrease total renal blood flow in
isolated perfused [60,75,76] and in situ kidneys of the
anesthetized dog [57—59]. However, as stated earlier,
indomethacin has not been found to decrease renal
blood flow in conscious dogs [53,61,62]. A possible
explanation for these differences is that the effect of
prostaglandin inhibition to increase renal vascular
resistance may be demonstrable primarily when the
baseline renal vascular resistance is high. In the
anesthetized state, the increased renal vascular resis-
tance may be due to increased activity of the renin-
angiotensin or adrenergic systems or of both.
Supporting evidence for prostaglandins as modu-
lators of renal vascular tone is the finding that stimuli
which result in decreases in renal blood flow enhance
renal production of prostaglandin-like substances.
For example, in the anesthetized dog or perfused
rabbit kidney, the intrarenal administration of vaso-
constrictors such as angiotensin 1 [77], angiotensin II
[24], norepinephrine [78] or epinephrine [78] or the
application of stimuli that lower renal blood flow
such as renal nerve stimulation [79], renal artery
clamping [80] or renal ischemia [81] results in en-
hanced amounts of prostaglandin-like substances in
renal venous effluent. Moreover, the administration
of prostaglandin synthesis inhibitors such as in-
domethacin or meclofenamate results in decreases in
prostaglandin-like substances in renal venous effluent
in anesthetized dogs following angiotensin Il [23,77]
norepinephrine [24,77], lowering of renal perfusion
pressure [82,83] and following methoxamine and
angiotensin II in the conscious dog [62]. Collectively,
these findings suggest that endogenous prostaglandins
may act to attentuate a variety of renal vasocon-
strictor stimuli in perfused kidneys and anesthetized
dogs. However, it should be noted that the stimuli
applied to decrease renal blood flow in these studies
is frequently of a supra-physiologic nature. Thus,
renal prostaglandins may exert their vasodilatory ef-
fects only when the kidney is severely ischemic, and
the absence of an effect of prostaglandin inhibition
in the conscious state argues against an effect of
prostaglandins under normal unstressed circum-
stances.
The mechanism of prostaglandin release during
renal ischemia is not clear but there is evidence sug-
gesting a role for a circulating substance. Specifically,
an ipsilateral decrease in renal perfusion pressure has
been found to increase prostaglandin release from
both kidneys [80]. Since reduction in renal perfusion
pressure is known to increase renin-angiotensin activ-
ity, angiotensin is a potential mediator of pros-
taglandin release during renal ischemia. Such a pro-
posal is particularly attractive since, as already
discussed, the intrarenal infusion of angiotensin has
been shown to increase prostaglandin concentrations
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in renal venous blood [24]. There is a recent experi-
mental observation which supports the role of endog-
enous angiotensin as a mediator of prostaglandin
release during renal ischemia. Inhibition of pros-
taglandin synthesis with meclofenamate or in-
domethacin has been shown to accentuate the lower-
ing of renal blood flow during renal arterial clamping
[821. In this study there was also evidence that this
further decrease in renal blood flow was due to inhib-
ition of angiotensin-mediated increases in pros-
taglandins. This interpretation was reasonable since
a competitive inhibitor of angiotensin II abolished
the effect of meclofenamate or indomethacin to fur-
ther lower renal blood flow [82].
While an inhibitor of angiotensin II may block the
effect of renal arterial clamping and angiotensin II to
increase renal venous prostaglandins, the effect of
epinephrine and renal nerve stimulation to increase
prostaglandin release is not altered by the prior in-
fusion of an angiotensin II inhibitor [77,78]. Alpha-
adrenergic blockade with phenoxybenzamine, how-
ever, has been shown to abolish the release of pros-
taglandin-like substances in response to renal nerve
stimulation and intrarenal epinephrine infusion
[77,78]. Thus, there seems to be evidence that both
angiotensin 11 and alpha-adrenergic stimulation may
be involved in stimulating renal prostaglandin re-
lease. At this time, however, it is not possible to
ascertain whether this is a direct effect of angiotensin
II and alpha-adrenergic agonists on prostaglandin
synthesis or due to some secondary effect of these
agents on renal hemodynamics [84,85].
In addition to attenuating the effects of vasocon-
strictor influences on the kidney, prostaglandins also
may be a determinant of intrarenal blood flow distri-
bution. The prostaglandins were suggested initially to
alter renal blood flow distribution because of the
observation in anesthetized dogs that intrarenal doses
of PGE decrease para-aminohippurate extraction
[45,46]. Subsequently, utilizing radiolabelled micro-
spheres,. intrarenal PGE or arachidonic acid has been
demonstrated to result in greater fractional in-
crements in inner cortical than outer cortical blood
flow in perfused dog kidneys [75], anesthetized rabbit
kidneys [86] and anesthetized dog kidneys [87-89].
Moreover, inhibition of prostaglandin synthesis with
either indomethacin or meclofenamate results in frac-
tional decreases in inner cortical blood flow in the
perfused dog kidney [75] and in the in situ anesthe-
tized dog kidney [57]. In contrast to the above find-
ings, in a recent study in conscious dogs, in-
domethacin did not significantly alter intrarenal
blood flow distribution [61].
In addition to mediating intrarenal blood flow dis-
tribution, prostaglandins may mediate several causes
of renal vasodilatation [48,90—921. In this regard the
increases in renal blood flow following bradykinin
[48], furosemide [90], ethacrynic acid [91] and ure-
teral obstruction [92] have been found to be abol-
ished or attenuated by indomethacin administration.
There is thus evidence that prostaglandins may
attentuate the renal response to severe ischemic in-
sults, may cause redistribution of fractional blood
flow to the medulla and may mediate renal vasodila-
tation in certain circumstances. It must be acknowl-
edged, however, that the noncompetitive inhibitors of
prostaglandins used in many of these studies may
exert effects other than inhibition of prostaglandin
synthesis [93].
It should be emphasized that although the above
results suggest that renal prostaglandins influence
renal blood flow in certain situations, these results
should not be interpreted to indicate that pros-
taglandins mediate the phenomenon of autoregula-
tion of renal blood flow or glomerular filtration, In an
initial study by Herbaczynska-Cedro and Vane [83],
indomethacin and meclofenamate were found to im-
pair autoregulation of renal blood flow in can-
nulated, perfused kidneys. The baseline renal vascu-
lar resistance in these kidneys, however, was quite
high and increased even further after treatment with
indomethacin or meclofenamate. The possibility that
this impairment of renal autoregulation is specific
only for the isolated perfused dog kidney preparation
has been examined by several groups, including our
own, by using in situ nonperfused kidneys in dogs.
The results have been rather uniform as autoregula-
tion of renal blood flow and glomerular filtration rate
have been preserved in the presence of inhibition of
postaglaridin synthesis [58, 59, 94]. Furthermore, Ka-
loyanides, Ahrens and DiBona [76] have recently
demonstrated intact autoregulation of renal blood
flow and glomerular filtration rate following incre-
ments and decrements in renal perfusion pressure in
perfused dog kidneys pretreated with indomethacin.
Thus, while renal prostaglandins may attenuate the
effect of severe ischemic insults to the kidney,
these hormones do not seem to be responsible for
the phenomenon of autoregulation of renal blood
flow or glomerular filtration rate.
Prostaglandins and renal water excretion
The localization of prostaglandin synthesis to the
interstitial cells of the renal medulla and papilla [74]
and the epithelial cells of the medullary collecting
duct [95] has made it attractive to postulate that these
ubiquitous fatty acids may be involved in the control
of renal water excretion. In fact, this postulate has
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received support from a number of in vitro and in vivo
studies.
The effect of prostaglandins on basal as well as
vasopressin-, theophylline-, and cyclic adenosine
monophosphate (AM P)-stim ulated water transport
has been investigated in vitro in anuran membranes
[54, 96—101]. The results obtained in the toad bladder
[54, 97—101] reveal that PGE1 does not affect basal
water transport [54, 97, 99, 101]. However, PGE1
uniformly antagonizes the hydro-osmotic effect of
vasopressin [54, 97, 101] and theophylline [54, 97,
101], but not of cyclic AMP [54, 97]. Since vasopres-
sin increases cyclic AMP by stimulating adenyl cy-
clase and aminophylline increases cyclic AMP by
inhibiting phosphodiesterase (the degradative en-
zyme of cyclic AMP), PGE1 most likely affects water
transport at a step proximal to cyclic AMP gener-
ation. Such an effect of PGE1 may be by competing
with vasopressin or altering the hormone's affinity for
its binding to the adenyl cyclase receptor. Such an
effect on adenyl cyclase was further demonstrated by
the ability of PGEI to inhibit vasopressin-stimulated
adenyl cyclase activity in the kidney of the red hamp-
ster [102] and the inner medulla of the rat [103].
In vitro results obtained in the isolated collecting
duct of the rabbit demonstrated that PGE1 stimu-
lated both basal and theophylline-mediated water
movement [96]. This finding suggests that in the
mammalian nephron PGE1 may directly stimulate
adenyl cyclase activity. This property of PGE1 may
be concentration dependent, since at concentrations
above l0-7M PGE1 has been shown to increase cyclic
AMP accumulation in toad bladder epithelium [101,
104] and in inner medulla of the rat [104], as well as
to stimulate adenyl cyclase activity in the rat [106]. In
contrast, lower concentrations of PGE1 (<l07M) in-
hibit vasopressin-stimulated water transport and cy-
clic AMP generation [103, 104]. These dose-depen-
dent effects whereby PGE1 acts as an agonist at one
dose and an antagonist at another dose have im-
paired somewhat the emergence of a unifying concept
as to the role of prostaglandins in altering the water
permeability of vasopressin-sensitive membranes.
More recently, an attempt to better define the role
of endogenous prostaglandins in these in vitro sys-
tems has prompted the use of agents that either in-
hibit prostaglandin synthesis (such as indomethacin
or salicylates) [105] or agents that antagonize the
peripheral action of prostaglandins (phosphorylated
polymers of phioretin, PPP) [106]. With the ex-
ception of 7-oxa-l3-prostanoic acid, these inhibitors
appear to exert no direct hydro-osmotic effect and
thus may be assumed not to have intrinsic adenyl
cyclase stimulatory properties. However, these agents
do potentiate the effect of vasopressin in most [98,
100, 107, 108], but not all [99], studies. These studies
therefore reinforce the impression that endogenous
prostaglandins may modulate the cellular action of
vasopressin. The ability of some of these agents to
enhance the response to cyclic AMP [100, 107] sug-
gests an additional effect of these drugs at a site
beyond the generation of cyclic AMP, and thus they
may have an action independent of prostaglandin
inhibition. In this respect, indomethacin and meclo-
fenamate have been shown to have phosphodiester-
ase inhibitory properties with large doses used in
vitro [104]; however, PPP appears to have no such
property in the concentrations used [100]. The cellu-
lar mechanism whereby the employed agents affect
water transport therefore has not been fully eluci-
dated and cannot in all cases be ascribed entirely to
inhibition of endogenous prostaglandin activity.
A number of in vivo experiments also have been
performed to examine the effect of prostaglandins on
renal water excretion. The i.v. administration of
PGE1 in vasodepressor doses has been found to cause
a vasopressin-mediated antidiuresis [70], while the
intrarenal administration of PGE1 has been shown
uniformly to cause an increase in urine flow and free
water clearance [44—46]. The mechanism of the in-
trarenal effect of PGE1 is difficult to determine be-
cause of the associated increases in renal blood flow
and solute excretion, either of which may enhance
water excretion. in addition, similar increases in wa-
ter excretion have been observed during intrarenal
PGE1 administration in animals in a vasopressin-free
state [70]. These latter results suggested that PGEI
may enhance water excretion by increasing distal
fluid delivery out of the proximal tubule. Such a
proximal tubule effect of PGE1, however, does not
exclude an additional direct effect of prostaglandins
on the distal nephron or even an effect in modulating
the action of vasopressin. The latter possibility was
suggested by the finding that PGE1 decreases free
water reabsorption more profoundly than acetyl-
choline despite comparable solute excretion rates in
saline-expanded dogs [44]. Although the pros-
taglandins could interfere with water reabsorption
by causing a washout of medullary tonicity [109], the
excretion of a hypotonic urine suggested a direct
effect on the water permeability of the collecting duct
144].
In order to more directly assess the role of endog-
enous prostaglandins in the in vivo control of water
excretion, we examined the effect of meclofenamate
and indomethacjn on water excretion in anesthetized
hypophysectomized dogs undergoing a water diuresis
[110]. In these studies, pretreatment with either of
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these inhibitors of prostaglandins synthetase poten-
tiated the peripheral action of exogenous vasopressin.
These results therefore were compatible with an in
vivo effect of renal prostaglandins to inhibit the ac-
tion of vasopressin to stimulate cyclic AMP and
thereby to alter the water permeability of the collect-
ing duct. However, as previously discussed, these in-
hibitors of prostaglandin synthesis may decrease me-
dullary blood flow. Such a decrease in medullary
blood flow could diminish any "washout" of inter-
stitital hypertonicity and thereby enhance the os-
motic gradient for water movement without directly
altering the cellular action of vasopressin. Since
these inhibitors of prostaglandin have been shown
not to alter baseline renal hemodynamics in the con-
scious state, studies were performed in conscious man
and rat during a water diuresis. Both aspirin and
indomethacin administration enhanced the response
of urinary osmolality to exogenous vasopressin in
conscious rats and similar results were observed in
man pretreated with indomethacin [111,112]. As pre-
viously reported in the dog, these inhibitors of pros-
taglandin did not alter renal hemodynamics in con-
scious man or rat. These findings thus suggested that
prostaglandins also may inhibit the effect of vaso-
pressin to generate cyclic AMP in vivo, as has been
previously demonstrated in in vitro studies [96,1011.
Studies therefore were performed recently in our
laboratory to examine whether medullary cyclic
AMP concentrations are enhanced to a greater extent
by the same vasopressin dose administered to in-
domethacin-treated rats as compared to nontreated
control rats. The finding that indomethacin pre-
treatment enhanced the vasopressin-mediated in-
crease in medullary cyclic AMP provided further sup-
port that endogenous prostaglandins interfere with
the cellular action of vasopressin to generate cyclic
AMP [113]. Since large doses of indomethacin have
been shown to inhibit cyclic nucleotide phospho-
diesterase, the increase in cyclic AMP could have
resulted from this effect rather than inhibition of
prostaglandin synthesis. Medullary phosphodiester-
ase concentrations, however, were measured in these
studies and were found not be altered by in-
domethacin treatment (unpublished observation).
Moreover, acetylsalicyclic acid, another inhibitor of
prostaglandin synthesis, does not alter either adenyl
cyclase or phosphodiesterase and yet, as already men-
tioned, it enhances the effect of vasopressin in the
conscious rat [Ill].
Taken together, the evidence strongly suggests
that, as initiaIlyproposed by Grantham and Orloff
[96], prostaglandins play a role in the control of renal
water excretion by antagonizing the peripheral action
of ADH. This effect appears to be primarily mediated
by altering the effect of vasopressin to stimulate in-
tracellular cyclic AMP but an additional hemody-
namic effect may also be involved in studies per-
formed in anesthetized animals.
Whether a disturbance in this interaction of pros-
taglandins with vasopressin in the control of renal
water excretion is operant in pathologic states with
clinical relevance is at this time speculative. It is
possible, however, that since in the absence of these
fatty acids the renal response to vasopressin is en-
hanced, patients ingesting prostaglandin synthetase
inhibitors in large doses could be prone to develop
water retention and hyponatremia, particularly if wa-
ter intake is not controlled in the face of persistent
vasopressin secretion. Conversely, the study of a pos-
sible role for an increase in renal prostaglandin con-
tent in clinical settings in which the tubular response
to exogenous vasopressin is blunted, such as with
hypokalemia and hypercalcemia, could be an impor-
tant area for future investigation.
A recent preliminary report by Yamamoto, Share
and Shade [114] also suggests a further means by
which the prostaglandins might influence water ex-
cretion. These workers reported that ventricular-cis-
ternal perfusion of PGE2 in the anesthetized dog
induced an increase in circulating plasma concentra-
tions of antidiuretic hormone (ADH). Indeed, other
workers have demonstrated that the intracarotid in-
fusion of PGEZ may result in increases in urine os-
molality in rats independent of changes in mean arte-
rial blood pressure [115]. These observations raise the
possibility that brain prostaglandins may influence
ADH release, However, the available data are in-
adequate to establish whether the ADH-releasing ac-
tivity of PGE2 is simply a pharmacologic effect or
whether endogenous brain prostaglandins might also
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